Zepp Health Corp. to Report Fourth Quarter and Full Year 2021 Financial Results on March 17, 2022
BEIJING, March 1, 2022 /PRNewswire/ -- Zepp Health Corp. ("Zepp Health" or the "Company") (NYSE: ZEPP), a cloud-based healthcare services provider with world-leading smart wearable technology, today announced that it will report its fourth quarter and full year 2021 unaudited financial results before the market open on Thursday, March 17, 2022. Management will hold a conference call at 8:00 a.m....
Ascletis Announces Submission of Marketing Authorization Applications for Ritonavir in Eight Additional European Countries
-- Ritonavir marketing authorization applications have been submitted to Spain, Portugal, Italy, Belgium, Poland, Sweden, the Netherlands and Denmark HANGZHOU, China and SHAOXING, China, March 1, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that it has submitted marketing authorization applications for ritonavir (100 mg film-coated tablet) in eight additional European countries (Spain, Portugal, Italy, Belgium, Poland,...
Active agent in Australian-developed nasal spray >99.5% active against the Omicron SARS-CoV-2 variant
The antiviral agent in VIRALEZE™ antiviral nasal spray, SPL7013, achieved >99.5% reduction of virus infectivity (the maximal possible reduction) against the highly contagious Omicron variant of SARS-CoV-2 SPL7013 showed potent antiviral activity and was virucidal against the Omicron variant SPL7013 outperformed other antiviral agents used in marketed nasal sprays, including iota-carrageenan and nitric oxide, in the...
Lifebit and Boehringer Ingelheim announce partnership to capture transformational value of health data
Boehringer Ingelheim partners with Lifebit Biotech, Ltd. to build a scalable data, analytics, and infrastructure platform This collaboration aims at capturing translational disease insights from large external healthcare biobanks and maximizing value of data for drug discovery and precision medicine LONDON, March 1, 2022 /PRNewswire/ -- The...
How Regional Digital Healthcare App BookDoc Overcomes COVID-19
KUALA LUMPUR, Malaysia, March 1, 2022 /PRNewswire/ -- BookDoc is a multi-award-winning digital healthcare platform offering its users an end-to-end, comprehensive solution to healthcare at their fingertips. Founded in Malaysia in 2015, BookDoc has since been profitable for the past 4 or 5 years, and is now operational in total of 5 countries/regions (Malaysia, Singapore, Indonesia, Hong Kong and...
Terumo Establishes Group-wide ‘DE&I Philosophy’ to Further Cultivate a Diverse, Equitable and Inclusive Culture
TOKYO, Mar. 1, 2022 /PRNewswire/ -- Terumo Corporation (TSE: 4543) today announced that it has established a global "DE&I Philosophy" to further cultivate the culture of Diversity, Equity, and Inclusion (DE&I) at the Terumo Group. Additionally, a "DE&I Guiding Principle" has also been defined to ingrain DE&I norms of behavior in policies, processes,...
Innovent Biologics and AnHeart Therapeutics Receive NMPA Breakthrough Designation for Taletrectinib in ROS1-Positive Non-Small Cell Lung Cancer
SAN FRANCISCO and SUZHOU, China, March 1, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, together with AnHeart Therapeutics ("AnHeart"), a clinical-stage global biopharmaceutical company committed to developing novel precision oncology therapies, today jointly announced that the...
Global Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2022
Added 18,985 New Subscribers in 3Q22Revenues Up 9.1% YoY to RMB317.2 Million ($49.8 Million) Gross Profit Up 9.8% YoY to RMB269.9 Million ($42.4 Million)Operating Income Up 20.8% YoY to RMB149.7 Million ($23.5 Million) Non-GAAP Operating Income Up 18.6% YoY to RMB161.6 Million ($25.4 Million)Conference Call to be Held on March 1, 2022, at 8:00 a.m. ET HONG KONG, March...
Novavax Announces Extended Durability of Protection Against Infection and Disease in United Kingdom COVID-19 Vaccine Phase 3 Clinical Trial
- NVX-CoV2373 demonstrates protection against symptomatic and asymptomatic infection - High level of vaccine efficacy maintained over a 6-month period of surveillance - Continued reassuring safety profile in line with previous trials GAITHERSBURG, Md., March 1, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing...
MIM Software Inc. Announces Global Partnership with GenesisCare
CLEVELAND, Feb. 28, 2022 /PRNewswire/ -- MIM Software Inc. announced today a partnership with leading global provider of integrated cancer care, GenesisCare, to increase patient access to world-class care on a global scale. GenesisCare's clinical teams treat more than 400,000 patients at more than 440 locations for cancer treatment in the...
